Redhill Biopharma Ltd. (RDHL) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($103.7K FCF) & 52% Gross Margin
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 56/100 (D+) score, RDHL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.56) or 200D SMA ($0.81) invalidates the momentum regime and cuts Target Base ($0.42) toward Bear Floor ($0.33).
Redhill Biopharma Ltd. (RDHL) dropped -2.66% to $0.42, trading at 3% of its 52-week range ($0.38 – $1.6). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
https://www.bloomberg.com/news/articles/2026-10-27/congo-ebola-cases-top-10-000-as-violence-hits-health-workers
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in funding from the
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RDHL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RDHL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Redhill Biopharma Ltd. (RDHL) ranks #272 by composite RQD confidence (56/100, grade D+) and #966 by equity capitalization ($3.7M). Within this direct 5-issuer industry benchmark cohort, RDHL leads on earnings valuation at N/A trailing P/E, while ENLV leads on capital efficiency and profitability with -0.6% ROIC and — gross margin. RDHL currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RDHL
ACTIVE
Redhill Biopharma Ltd. | D+ | 56/100 | — | — | — | -2.66% | $3.7M | Benchmark Subject |
| ENLV Enlivex Ltd. | D- | 35/100 | — | — | -0.6% | -2.68% | $3.9M | /enlv-vs-rdhl → |
| ONCO Onconetix Inc. | D- | 36/100 | — | 77.6% | -35.0% | -1.99% | $3.5M | /onco-vs-rdhl → |
| ERNA Ernexa Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +6.57% | $3.4M | /erna-vs-rdhl → |
| GRI GRI Bio Inc. | D- | 38/100 | — | — | -35.0% | -3.38% | $3.4M | /gri-vs-rdhl → |
Redhill Biopharma Ltd. (RDHL) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Redhill Biopharma Ltd. (NASDAQ: RDHL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $0.42 (-2.66% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RDHL ranks #272 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDHL carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ENLV (Enlivex Ltd.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -0.6%, cap $3.9M) and ONCO (Onconetix Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, RDHL leads on earnings multiple (N/A) while ENLV leads on capital efficiency (-0.6% ROIC).
For Redhill Biopharma Ltd. (RDHL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
RDHL last traded at $0.42 (-2.66% on volume of 85,734 shares), positioning the stock -25.00% below its 50-day simple moving average ($0.56) and -48.15% below its 200-day simple moving average ($0.81). Across its 52-week range of $0.38 to $1.60, RDHL sits at the 3.3% percentile with a 14-day RSI of 33.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.47).
Why RDHL Stock dropped -2.66% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.